Amgen receives FDA priority review for tarlatamab BLA
Amgen has received US FDA priority review for its biologics licence application for tarlatamab to treat advanced small-cell lung cancer.
Amgen has received US FDA priority review for its biologics licence application for tarlatamab to treat advanced small-cell lung cancer.
What's Your Reaction?
